Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
November 03, 2021 16:01 ET
|
Sarepta Therapeutics, Inc.
Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior yearIn light of its continued over-performance, Sarepta raises its full-year...
Sarepta Therapeutics to Present at Upcoming Investor Conferences
November 02, 2021 16:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 29, 2021 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 29, 2021...
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
October 27, 2021 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial...
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
October 13, 2021 21:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an...
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021
October 12, 2021 16:04 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial...
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
October 12, 2021 16:01 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (Nasdaq:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to sell,...
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
October 11, 2021 09:13 ET
|
Sarepta Therapeutics, Inc.
Results presented at ‘Micro-dystrophin Day’ highlight breadth, depth and strength of the clinical evidence to date for SRP-9001 in treating Duchenne muscular dystrophy; tolerability profile remains...
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
October 04, 2021 16:30 ET
|
Sarepta Therapeutics, Inc.
Center dedicated to research and development activities to advance Sarepta’s industry-leading, multi-platform pipelineThe Center encompasses 85,000 square feet of space, tripling Sarepta’s footprint...
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
October 04, 2021 07:00 ET
|
Sarepta Therapeutics, Inc.
- Sarepta to host “SRP-9001 Micro-dystrophin R&D Day” at 8:30 a.m. Eastern Time on Monday, Oct. 11, 2021 CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc....